Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS)

被引：2
|
作者：
Cervera, J. [1 ]
Sole, F.
Haase, D.
Luno, E.
Such, E.
Nomdedeu, B.
Costa, D.
Bernal, T.
Vallespi, T.
Bueno, J.
Pedro, C.
Mallo, M.
Ardanaz, M. T.
Calasanz, M. J.
del Canizo, C.
Hernandez-Rivas, J. M.
Schanz, J.
Steidl, C.
Hildebrandt, B.
Carbonell, F.
Orero, M.
Ramos, F.
Marco, V.
Tormo, M.
Gomez, V.
Andreu, R.
Xicoy, B.
Amigo, M. L.
Munoz, J. A.
Bonanad, S.
Arrizabalaga, B.
Senent, M. L.
Germing, U.
Sanz, G. F.
机构：
[1] Univ Gottingen, D-3400 Gottingen, Germany
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70110-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S75 / S76
页数：2
相关论文
共 50 条
  • [21] Prognostic relevance of cytogenetic systems in myelodysplastic syndromes
    Belli, Carolina B.
    Bestach, Yesica
    Correa, Walter A.
    Sakamoto, Francisco
    Flores, Maria G.
    Basquiera, Ana L.
    Rivas, Maria M.
    Campestri, Reinaldo
    Bengio, Raquel
    Larripa, Irene
    LEUKEMIA & LYMPHOMA, 2012, 53 (08) : 1640 - 1642
  • [22] THE IMPACT OF MYELODYSPLASTIC SYNDROMES (MDS) ON THE MENTAL HEALTH OF PATIENTS AND CAREGIVERS
    Scheurmeyer, Isabel
    Hughes, Mary
    Sloan, Erika
    LeBlanc, Thomas
    Houk, Alice
    Sirewu, Nyaradzo
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [23] Impact of obesity on survival of patients with myelodysplastic syndromes
    Schwabkey, Zaker
    Al Ali, Najla
    Sallman, David
    Kuykendall, Andrew
    Talati, Chetasi
    Sweet, Kendra
    Lancet, Jeffrey
    Padron, Eric
    Komrokji, Rami
    HEMATOLOGY, 2021, 26 (01) : 393 - 397
  • [24] Cytogenetic findings and their prognostic impact in myelodysplastic syndrome patients
    Banescu, Claudia
    Benedek, Istvan
    Duicu, Carmen
    Demian, Smaranda
    Voidazan, Septimiu
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2011, 19 (02): : 139 - 147
  • [25] Prognostic relevance of cytogenetic subgroups in 357 patients with myelodysplastic syndromes.
    Haase, D
    Schanz, J
    Wulich, J
    Schoch, C
    Freund, M
    Haferlach, T
    Wormann, B
    Staib, P
    Lentini, G
    Bartels, H
    Geissler, RG
    Germing, U
    Dorges, U
    Fonatsch, C
    Hiddemann, W
    BLOOD, 1997, 90 (10) : 2232 - 2232
  • [26] A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers
    De Roos, Anneclaire J.
    Deeg, H. Joachim
    Davis, Scott
    CANCER CAUSES & CONTROL, 2007, 18 (10) : 1199 - 1208
  • [27] A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers
    Anneclaire J. De Roos
    H. Joachim Deeg
    Scott Davis
    Cancer Causes & Control, 2007, 18
  • [28] Conventional cytogenetic (CC), fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) analysis in patients with myelodysplastic syndromes (MDS)
    Skonieczka, Olga Haus
    Duszenko, Ewa
    Mucha, Barbara
    Babicz, Mariusz
    Wyrowinska, Elzbieta
    Swistek, Wojciech
    CHROMOSOME RESEARCH, 2007, 15 : 203 - 204
  • [29] Pregnancy in patients with myelodysplastic syndromes (MDS)
    Volpicelli, P.
    Latagliata, R.
    Breccia, M.
    Carmosino, I.
    Stefanizzi, C.
    Iannella, E.
    Levi, A.
    Natalino, F.
    Alimena, G.
    LEUKEMIA RESEARCH, 2007, 31 : S107 - S107
  • [30] Phase II study of amifostine in patients with myelodysplastic syndromes (MDS): Impact on hematopoiesis.
    List, AF
    Holmes, H
    Vempaty, H
    Greenberg, PL
    Bennett, JM
    BLOOD, 1998, 92 (10) : 714A - 714A
12345